SecurityFRAK / Market Vectors Unconventional Oil & Gas ETF (92189F668)
Institutional Owners27
Institutional Shares2,764,096
Institutional Value$ 40,998,000 USD

Institutional Stock Ownership and Shareholders()

FRAK / Market Vectors Unconventional Oil & Gas ETF Institutional Ownership

Market Vectors Unconventional Oil & Gas ETF (NYSE:FRAK) has 27 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 2,764,096 shares. Largest shareholders include Janney Capital Management LLC, Wells Fargo & Company/mn, Bank Of America Corp /de/, Morgan Stanley, Susquehanna International Group, Llp, Citadel Advisors Llc, Citadel Advisors Llc, Janney Montgomery Scott LLC, Private Capital Management Inc, and Royal Bank Of Canada.
Market Vectors Unconventional Oil & Gas ETF (NYSE:FRAK) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/frak"><img src="https://images.fintel.io/us-frak-so.png" alt="FRAK / Market Vectors Unconventional Oil & Gas ETF Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-05-14 13F-HR NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO 600 600 0.00 9 9 0.00
2018-05-15 13F-HR ADVANTAGE INVESTMENT MANAGEMENT, LLC 66 66 0.00 1 1 0.00
2018-05-11 13F-HR First Allied Advisory Services, Inc. 200 0 -100.00 3 0 -100.00
2018-05-11 13F-HR PNC FINANCIAL SERVICES GROUP, INC. 0 135 0 2
2018-05-11 13F-HR MML INVESTORS SERVICES, LLC 30,710 0 -100.00 481 0 -100.00
2018-05-11 13F-HR CITADEL ADVISORS LLC 52,551 779
2018-05-18 13F-HR/A ROYAL BANK OF CANADA 5,783 14,345 148.05 90 213 136.67
2018-04-19 13F-HR Janney Montgomery Scott LLC 48,297 716
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP 33,559 79,520 136.96 526 1,179 124.14
2018-05-15 13F-HR Parallax Volatility Advisers, L.P. 1 1 0.00 0 0
2018-04-18 13F-HR Creative Planning 155,574 0 -100.00 2,436 0 -100.00
2018-05-15 13F-HR LADENBURG THALMANN FINANCIAL SERVICES INC 265 265 0.00 4 4 0.00
2018-05-02 13F-HR Fusion Family Wealth LLC 46 46 0.00 1 1 0.00
2018-05-02 13F-HR WELLS FARGO & COMPANY/MN 229,712 241,759 5.24 3,598 3,585 -0.36
2018-05-09 13F-HR ENVESTNET ASSET MANAGEMENT INC 5,034 9,389 86.51 79 139 75.95
2018-04-17 13F-HR FARMERS & MERCHANTS INVESTMENTS INC 2,900 1,933 -33.34 45 29 -35.56
2018-05-09 13F-HR IFP Advisors, Inc 677 499 -26.29 11 7 -36.36
2018-05-15 13F-HR JANE STREET GROUP, LLC 0 10,029 0 149
2018-05-17 13F-HR Atlantic Trust Group, LLC 215 215 0.00 3 3 0.00
2018-05-15 13F-HR BANK OF AMERICA CORP /DE/ 45,963 126,818 175.91 720 1,881 161.25
2018-02-15 13F-HR Bb&t Investment Services, Inc. 1,530 1,530 0.00 22 24 9.09
2017-01-13 13F-HR MetLife Securities, Inc 1,683 31
2017-10-26 13F-HR PRIVATE CAPITAL MANAGEMENT INC 14,750 14,750 0.00 206 219 6.31
2018-05-14 13F-HR MORGAN STANLEY 108,190 96,178 -11.10 1,694 1,426 -15.82
2018-05-15 13F-HR UBS Group AG 4,200 3,340 -20.48 66 50 -24.24
2018-05-14 13F-HR/A CITADEL ADVISORS LLC 91,399 52,551 -42.50 1,431 779 -45.56
2018-05-15 13F-HR CAPTRUST FINANCIAL ADVISORS 1,073 1,073 0.00 17 15 -11.76
2018-05-14 13F-HR CHILTON CAPITAL MANAGEMENT LLC 27,223 0 -100.00 426 0 -100.00
2018-05-15 13F-HR MANUFACTURERS LIFE INSURANCE COMPANY, THE 150 150 0.00 2 2 0.00
2018-05-10 13F-HR SMITHFIELD TRUST CO 2,200 2,200 0.00 34 33 -2.94
2018-05-11 13F-HR Cutler Group LP 100 0 -100.00 1 0 -100.00
2018-04-19 13F-HR Janney Capital Management LLC 1,021,936 2,004,013 96.10 16,003 29,720 85.72
2018-05-08 13F-HR Parallel Advisors, LLC 160 160 0.00 3 2 -33.33

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

CUSIP: 92189F668